The $ 4^{th} $ NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?
Abstract Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising “lead” for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Pediatric rheumatology - 21(2024), Suppl 1 vom: 05. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Canna, Scott W. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Biomarker driven trials |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12969-023-00867-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054282136 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054282136 | ||
| 003 | DE-627 | ||
| 005 | 20240203064704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240106s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12969-023-00867-y |2 doi | |
| 035 | |a (DE-627)SPR054282136 | ||
| 035 | |a (SPR)s12969-023-00867-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Canna, Scott W. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The $ 4^{th} $ NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Abstract Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising “lead” for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies. | ||
| 650 | 4 | |a IL-18 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IL-18 blocker |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Refractory SJIA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biomarker driven trials |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IL-18ophathies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammasopathies |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a De Benedetti, Fabrizio |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric rheumatology |d London : BioMed Central, 2003 |g 21(2024), Suppl 1 vom: 05. Jan. |w (DE-627)SPR029041112 |w (DE-600)2279468-2 |x 1546-0096 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:Suppl 1 |g day:05 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12969-023-00867-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e Suppl 1 |b 05 |c 01 | ||